Remember when Barack Obama declared that businesses owed their success to the government? “You didn’t build that,” he said. Well, now the National Institutes of Health is claiming credit for Biogen’s new Alzheimer’s treatment that showed success in a large trial last week.
“Potentially promising outcomes such as this one are the result of sustained public investment in medical research, the tireless work of scientists around world, and the help of people living with Alzheimer’s and their caregivers,” the NIH wrote in a press release this week. Although the NIH didn’t fund the successful study, it says its “decades of research paved the way” for it.